Sponsored Symposium 4B

Pulmonary arterial hypertension (PAH) treatment continues to evolve with improved strategies and newer therapies ultimately improving the lives of our patients. The recent 2022 ESC/ERS guidelines provide data-derived reference to apply currently available management strategies. Risk assessment in PAH has improved our ability to prognosticate and anticipate changes in our PAH patients. This lecture will emphasize the need for accurate and timely PAH diagnosis, overview value of risk assessment tools, and review the treatment algorithm for PAH.